NDAORALTABLET, EXTENDED RELEASE
Approved
Oct 2017
Lifecycle
LOE Approaching
Competitive Pressure
15/100
Clinical Trials
20
Data completeness
7/8 — Comprehensive
LYRICA CR (pregabalin) by Viatris (2) is 2 ‑delta site (an auxiliary subunit of voltage‑gated calcium channels) in central nervous system tissues. Approved for diabetic peripheral neuropathic pain, postherpetic neuralgia, epilepsy and 1 more indications. First approved in 2017.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LYRICA CR is an extended-release oral formulation of pregabalin, a small-molecule CNS agent that binds to alpha-2-delta subunits of voltage-gated calcium channels to reduce neuropathic pain and seizures. It is indicated across 16 conditions including diabetic peripheral neuropathy, postherpetic neuralgia, fibromyalgia, epilepsy, and anxiety. The drug modulates calcium-dependent neurotransmitter release and enhances GABA transport without direct GABA receptor binding.
$0.4MPart D
LOE Approaching12mo to LOEMinimal Part D penetration signals limited commercial team scale; approaching loss of exclusivity in May 2027 will accelerate generic pressure and workforce contraction.
Mechanism of Action
2 ‑delta site (an auxiliary subunit of voltage‑gated calcium channels) in central nervous system tissues. Although the mechanism of action of pregabalin has not been fully elucidated, results with genetically modified mice and with compounds structurally related to pregabalin (such as gabapentin)…
Indications (4)
Worked on LYRICA CR at Viatris (2)? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.